CSL Behring cuts nearly 10% of jobs at Bern site

Nearly 10% of jobs have disappeared from one of Bern’s biggest industrial employers. CSL Behring has completed a sweeping restructuring at its Swiss site, confirming that the pharmaceutical group has cut just under a tenth of its workforce in the capital. The announcement lands months after reports first warned that around 180 positions could be at risk—an alarming prospect for a region where the company is a major industrial anchor.

The Australian group frames the overhaul as a strategic reset rather than a retreat. In a statement issued on Thursday, CSL Behring said the transformation had “strengthened its long-term competitiveness and positioned it for the future”. The company did not disclose the final number of jobs eliminated.

That silence leaves a crucial question unanswered: how many Bern employees ultimately lost their positions? CSL Behring says the cuts were kept below the level initially feared, but the impact remains significant. The Bern operation is not a marginal outpost; it ranks among the region’s largest industrial employers and remains one of the group’s most important production sites worldwide. For Bern’s labour market, the restructuring marks a sharp reminder that even globally critical pharmaceutical operations are under pressure to adapt.

The restructuring was not a simple headcount purge: more than 100 new roles emerged as old positions vanished. CSL Behring says the transformation allowed many employees to move into new jobs within the company, softening the blow for its workforce while reshaping the skills needed at the Bern site.

That contrast is the heart of the announcement. On one side, the company has eliminated just under 10% of its jobs. On the other, it has created more than 100 positions, signalling a shift in responsibilities and capabilities rather than an across-the-board withdrawal from Bern. The available figures do not show how many employees transferred, how many left, or how many vacancies remain; CSL Behring has provided no more specific breakdown.

For workers, however, a new role is not automatically an easy transition. Internal redeployment can mean retraining, altered responsibilities and uncertainty over long-term prospects. The company credits employees’ commitment for limiting the cuts, saying many found opportunities inside the organisation. The restructuring therefore carries two messages at once: CSL Behring is reducing employment in Bern, yet it is also investing in a different model of work at the site. What that model means in practice will become clearer as the new positions settle into the operation.

Bern is absorbing a major employment shock at a site that matters far beyond the city limits. CSL Behring describes its Bern facility as one of the group’s most important production sites worldwide. Its local importance is equally pronounced: the operation is one of the region’s largest industrial employers, linking the pharmaceutical sector to the wider Swiss economy through skilled work and industrial capacity.

The company’s decision highlights the tension facing Switzerland’s life-sciences industry. Pharmaceutical production remains a pillar of the country’s high-value economy, but major sites must continually reorganise to remain competitive. CSL Behring says the Bern transformation is intended to secure its future position. Yet the immediate arithmetic is stark: fewer than one in ten jobs has been cut, while more than 100 new positions have been introduced in parallel.

The restructuring also carries a regional message. Bern’s industrial base depends not only on headline investment but on the stability of large employers and the skills they retain. Redeployment may preserve expertise within CSL Behring, but job losses still affect households, suppliers and the local labour market. The company’s global importance may protect the site from becoming expendable; it does not shield Bern from the disruption of corporate change.

The restructuring is complete, but its consequences are only beginning to emerge. CSL Behring insists that Bern is now better positioned for the future, pointing to the creation of more than 100 new positions and the movement of many employees into fresh roles. The company’s stated ambition is clear: make the site more competitive while preserving its place in the global production network.

The next test will be whether that promise translates into durable employment and continued industrial strength. CSL Behring has not published a precise final figure for the jobs eliminated, nor has it detailed the new roles, the affected departments or the skills required. Those gaps leave employees, policymakers and the wider region without a complete picture of the transformation.

For Switzerland, the case is closely watched. A large pharmaceutical site can remain strategically important while still cutting staff—a contrast that is increasingly central to the country’s economic debate. Bern now faces the challenge of converting organisational change into lasting opportunity. If the new positions build expertise and production capacity, the cuts may mark a difficult transition. If not, the restructuring could become an early warning for a region confronting a leaner industrial future.